ReviewJournal of nanobiotechnology2021
Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics.
Review in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Reductant-Responsive Squalene Dual-Prodrug Nanoparticles Co-Delivering Doxorubicin and Exatecan for Synergistic Breast Tumor Therapy.Pharmaceutics · 2026Article
- Engineered Xenogeneic Bone Scaffold with IL-10 Nanodelivery System: Immunomodulation and BMSC Fate Programming for Skull Defect Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A multifunctional injectable MPDA@MTIC-Co hydrogel platform for synergistic chemotherapy-photothermal therapy of postoperative glioblastoma.Bioactive materials · 2026Article
- NIR-elicited nanoplatform amplifies cancer ferrotherapy in uveal melanoma via synergistic ferroptosis induction and glucose metabolism intervention.Materials today. Bio · 2026Article
- Bio-inspired suction cup microneedle loaded fusion membrane targeting nano-drug delivery system treat androgenetic alopecia.Journal of nanobiotechnology · 2026Article
- Engineered T cell membrane coated nanoparticles reverse thermo-resistance and reprogram tumor microenvironment to synergistically potentiate bladder cancer photothermal immunotherapy.Journal of nanobiotechnology · 2026Article
- Microenvironment-responsive nanomotors enable enhanced biofilm penetration and immune reprogramming for peri-implantitis therapy.Journal of nanobiotechnology · 2026Article
- Bioactive eggshell membrane-integrated nanofiber dressing with mesoporous polydopamine-mediated sustained dexamethasone delivery for enhanced wound regeneration.Journal of nanobiotechnology · 2026Article
- A novel mRNA nanovaccine with dual immunoregulation ameliorates rheumatoid arthritis and associated pneumonia.Asian journal of pharmaceutical sciences · 2026Article
- Hollow-core polydopamine nanocarriers for ultrasound-enhanced drug delivery.Nanoscale horizons · 2026Article
- Emodin-Based Drug Delivery Systems: Therapeutic Applications in Inflammatory Diseases.International journal of nanomedicine · 2026Review
- Biomimetic nanotherapy forInternational journal of pharmaceutics: X · 2025Article
- A Universal Approach Using Water-Soluble Templates for Meso- and Macro-Porous Organic Polymers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- An aptamer-conjugated mesoporous polydopamine formulation for synergistic targeted and photothermal therapy of hepatocellular carcinoma.International journal of pharmaceutics: X · 2025Article
- Injectable hydrogel microsphere orchestrates immune regulation and bone regeneration via sustained release of calcitriol.Materials today. Bio · 2025Article
- Macrophage membrane-coated polydopamine nanomedicine for treating acute lung injury through modulation of neutrophil extracellular traps and M2 macrophage polarization.Materials today. Bio · 2025Article
- Polydopamine Nanocomposite Hydrogel for Drug Slow-Release in Bone Defect Repair: A Review of Research Advances.Gels (Basel, Switzerland) · 2025Review
- Enhanced integrated therapy for breast cancer employing Honokiol-loaded mesoporous polydopamine nanoparticles in conjunction with photothermal effects and low-dose metformin.APL bioengineering · 2025Article
- Iron chelators loaded on myocardiocyte mitochondria-targeted nanozyme system for treating myocardial ischemia-reperfusion injury in mouse models.Journal of nanobiotechnology · 2025Article
- Orchestrating cancer therapy: Recent advances in nanoplatforms harmonize immunotherapy with multifaceted treatments.Materials today. Bio · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Polydopamine (PDA), which is derived from marine mussels, has excellent potential in early diagnosis of diseases and targeted drug delivery owing to its good biocompatibility, biodegradability, and photothermal conversion. However, when used as a solid nanoparticle, the application of traditional PDA is restricted because of the low drug-loading and encapsulation efficiencies of hydrophobic drugs. Nevertheless, the emergence of mesoporous materials broaden our horizon. Mesoporous polydopamine (MPDA) has the characteristics of a porous structure, simple preparation process, low cost, high specific surface area, high light-to-heat conversion efficiency, and excellent biocompatibility, and therefore has gained considerable interest. This review provides an overview of the preparation methods and the latest applications of MPDA-based nanodrug delivery systems (chemotherapy combined with radiotherapy, photothermal therapy combined with chemotherapy, photothermal therapy combined with immunotherapy, photothermal therapy combined with photodynamic/chemodynamic therapy, and cancer theranostics). This review is expected to shed light on the multi-strategy antitumor therapy applications of MPDA-based nanodrug delivery systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.